Plné znění - 2/2008 Sb. m. s.

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 16. xxxxxxxxx 2007 bylo xxxxxxxxxx xxxxxxxxx XXXXXX, xxxxxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx¹⁾, xxxxxxxx xxxxxxxxx xxxxxx xxxxx Přílohy I - Xxxxxxx xxxxxxxxxx látek x metod dopingu.

Xxxxxxx I xxxxxxxxx x xxxxxxxx x xxxxxxx x článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2008 x xxxxx xxxx xxxxxxxxx x xxxxxxxx x xxx Xxxxxx republiku. Xxxx xxxxxx Přílohy I x platnost xxxxxxxx xxxxxx Xxxxxxx I Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx ve xxxxxx xx xxxxx xxx xxx 2007, xxxxxxxxx xxx x. 59/2007 Xx. x. s.

Xxxxxxxx xxxxx Přílohy X x xxxx xxxxxxx do xxxxxxx xxxxxx xx vyhlašují xxxxxxxx.

X1. ANABOLICKÉ XXXXX

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX):

x. Xxxxxxxx * XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-xxxxxxxxxxxxx (5α-androst-1-en-3,17-dion); xxxxxxxxx (19-xxxxxxxxxxxxxxxx); xxxxxxxxxx; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); dehydrochlormethyltestosteron (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; ethylestrenol (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; xxxxxxxxxx; furazabol (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-hydroxy-17α-metylestra-4,9-dien-3-on); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxx-1-xx-3-xx); methylnortestosteron (17β-xxxxxxx-17α-xxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9,11-xxxxx-3-xx); methyltestosteron; xxxxxxxxx; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); norboleton; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; oxandrolon; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx ([3,2-x]xxxxxxx-5α-xxxxxxxxxxxxxx-17β-xxxxxxxxxxxxxxxxx); xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; 1-xxxxxxxxxxx (17β-hydroxy-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); xxxxxxxxx x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

b. Xxxxxxxxx ** AAS:

Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, prasteron (xxxxxxxxxxxxxxxxxxxxx, XXXX), xxxxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx x xxxxxxx:

5α-xxxxxxxxx-3α,17α-xxxx xxxxxxx-5-xx-3β,17α-xxxx

5α-xxxxxxxxx-3α,17β-xxxx 4-xxxxxxxxxxxxx (androst-4-en-3β,17β-diol)

5α-androstan-3β,17α-diol 5-androstendion (xxxxxxx-5-xx-3,17-xxxx)

5α-xxxxxxxxx-3β,17β-xxxx xxx-xxxxxxxxxxxxxxxxxx

androst-4-en-3α,17α-diol 3α-hydroxy-5αandrostan-17-on

xxxxxxx-4-xx-3α,17β-xxxx 3β-xxxxxxx-5αxxxxxxxxx-17-xx

xxxxxxx-5-xx-3β,17α-xxxx 19-xxxxxxxxxxxxxx

xxxxxxx-5-xx-3α,17α-xxxx 19-xxxxxxxxxxxxxxxxx

androst-5-en-3α,17β-diol

X xxxxxxxxx, kdy může xxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxx, xxxx xx mít xx xx, xx Xxxxxx xxxxxxxx xxxx Xxxxxxxxx xxxxx x xxxx hlášen pozitivní Xxxxxxxxx laboratorní xxxxx, xxxx xx xxxxxxxxxxx Xxxxxxxx látky nebo xxxxxx xxxxxxxxxx xxxx xxxxxxxxxxx a/nebo když xx jakýkoli xxxx xxxxxxxxx xxxxx xx Xxxxxx Xxxxxxxxx významně xxxxxxxxx od xxxxxxx xxxxxx, které xx xxxxxxxx vyskytují x xxxx xxx, xx xxxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx. Xxxxxx se xxx xx xx, xx Xxxxxx xxxxxxxx Xxxxxxxxx xxxxx v xxxxxxx případě, pokud Xxxxxxxxx xxxxxxx, xx xx koncentrace Xxxxxxxx xxxxx nebo xxxxxx xxxxxxxxxx xxxx xxxxxxxxxx x/xxxx xxxxxxxxx poměr xx Xxxxxx Sportovce xxxxxxxx xxxxxxxxxxxxx xxxx xxxxxxxxxxxx xxxxxx.

Xxxx xx mít za xx, xx Xxxxxx Xxxxxxxxx xxxxxxxx Zakázanou xxxxx a laboratoř xxxxxxx Xxxxxxxxx xxxxxxxxxxx xxxxx xx xxxxx xxxxxxxxx a xxx xxxxxxxxx xxxxxxxxxxx, xxxxx xxx xxxxx spolehlivé xxxxxxxxxx xxxxxx (xxxx. XXXX) xxxxxxxx, že xx Xxxxxxxx xxxxx xxxxxxxxxx xxxxxx. X xxxxxxx xxxxxxx xxxx xxxxx xxxxxxxx další xxxxxxx.

Xxxx xx xxxxxxx xxxxxxxx analýzy xxxxxxxx xxxxxxxxxxx xx xxxxxxx xxxxxx, které xx xxxxxxxx vyskytují x xxxx x xxxxx xxxxxxxxxx analytická xxxxxx (xxxx. XXXX) xxxxxxxxxxx xxxxxxxx xxxxx Xxxxxxxx látky, xxx xxxxxxxx známky použití Xxxxxxxx látky, xxxx xxxx. xxxxxxxxx s xxxxxxxxxxx referenčními steroidními xxxxxxx, xxxx xxxx xxxxxxxxx xxxxxxxxx xxxxx X/X xxxxx xxx xxxxx (4) ku xxxxx (1) x xxxxx xxxxxxxxxx analytická xxxxxx (xxxx. IRMS) xxxxxxxxxxx xxxxxxxx xxxxx xxxxx, xxxxxxx xxxxxxxxx Xxxxxxxxxxxxx organizace další xxxxxxx porovnáním výsledků xxxxxxxxxx testů xxxx xxxxxxxxxx xxxxxxxxxx testů.

Xx-xx xxxxxxxxxx xxxxxx xxxxx xxxxxxx, pak xxxxxxxx bude xxxxxxxxxx xxxxxx xxxx xxxxxxxxx x xx jako xxxxxxxxx. Xxxxx laboratoř xxxxxxx, za xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. XXXX) xxxxxxxx xxxxx Zakázané látky, xxxx xxxxx xxxxxxxx xxxxx xxxxxxx, x xxxx xx xxx xx to, xx Xxxxxx xxxxxxxx Xxxxxxxxx xxxxx. Xxxxx nebyla xxxxxxx xxxxxxxxxx analytická xxxxxx (xxxx. XXXX) x xxxxxx x xxxxxxxxx xxxxxxxxx 3 xxxxxxxxx xxxxx, xxxx xxxxxxx xxxxxxxxxxxxxx profil Xxxxxxxxx tím, xx xxxx xxxxxxxxxx Antidopingovou xxxxxxxxxx x xxxxxxxxxxxxx 3 xxxxxxxx xxxxxxx xxxxxxxx xxx xxxxxxxxxxx xxxxxxxx. Xxxxxxxx, xxxxx xxxxxxxxxx tuto xxxxxxxxxxxxxx xxxxxx, bude xxxxxx xxxx neobvyklý. Pokud xxxxxxxxxxxxxx xxxxxx Sportovce, xxxxxxxx následnými xxxxx, xxxx xxxxxxxxxxxx xxxxxxxx, xxxx se xxx xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx nález.

X xxxxxxxx xxxxxxxx individuálních xxxxxxxxx xxxx xxx x xxxx xxxxxx xxxxxxx boldenon xxxxxxxxxxx xxxxxx ve velice xxxxxx xxxxxxxxxxxxx (xx/xx). Xxxxx xxxxxxxxx xxxxxx xxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxx analytické xxxxxx (např. IRMS) xxxxxxxxxxx xxxxxxxx původ Xxxxxxxx xxxxx, xxxx xxx provedeno xxxxx xxxxxxx provedením xxxxxxxxxx xxxxx (xxxxxxxxxx xxxxx).

Xxxxx xxxxxxxxx nahlásila Xxxxxxxxx xxxxxxxxxxx xxxxx 19-xxxxxxxxxxxxxxx, bude xx xx xxxxxxxxx za xxxxxxx a xxxxxxxxxxx xxxxx exogenního původu Xxxxxxxx xxxxx. X xxxxxxx xxxxxxx xxxx xxxxx xxxxxxxx xxxxx xxxxxxx.

X xxxxxxx, xx Sportovec xxxxxx xxxxxxxxxxxxx xxx dalších xxxxxxxxx, xxxx xx xxx xx xx, xx Vzorek Xxxxxxxxx xxxxxxxx Xxxxxxxxx látku.

2. Ostatní xxxxxxxxxx xxxxx, xxxxxxxxxx:

Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx androgenových xxxxxxxxx (SARM), xxxxxxx, xxxxxxx, xxxxxxxxxx, ale xx x xxxxxxxx xxxxx na ně.

X2. XXXXXXX A XXXXXXXX XXXXX

Následující xxxxx x xxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxxxx:

1. Xxxxxxxxxxxx (XXX);

2. Xxxxxxx hormon (xXX), xxxxxxxx podobné xxxxxxx faktory (xxxx. XXX-1), xxxxxxxxxx růstové xxxxxxx (MGF);

3. Xxxxxxxxxxxxx (např. XX, xXX), xxxxxxxx jen x xxxx;

4. Xxxxxxxx;

5. Kortikotropiny

x xxxxx xxxxx x podobnou chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

Xxxxx Xxxxxxxxx nemůže prokázat, xx xxxxxxxxxxx xxxx xxxxxxxxx fyziologickým xx xxxxxxxxxxxx xxxxxx, xxxx xx mít xx xx, že Vzorek xxxxxxxx Xxxxxxxxx xxxxx (xxx je xxxxxxx xxxx) v xxxxxxxxx, xxx koncentrace Xxxxxxxx xxxxx xxxx jejích xxxxxxxxxx xx xxxxxxxxxx x/xxxx xxxxxxxxx poměry xx Xxxxxx Xxxxxxxxx xxxxxxx překročí hodnoty xxxxxxxx zjištěné u xxxx tak, xx xxxxxxxxxxxx xxxxxxxx endogenní xxxxxxxx.

Xxxxx laboratoř xxxxxxxxx, po xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx, xx Zakázaná xxxxx xx exogenního původu, xxxx xx mít xx to, že Xxxxxx xxxxxxxx Xxxxxxxxx xxxxx a xxxx xxxxxxx Xxxxxxxxx xxxxxxxxxxx xxxxx.

S3. XXXX-2 XXXXXXXX

Všichni xxxx-2 xxxxxxxx xxxxxx xxxxxx D- a X-xxxxxxx xxxx xxxxxxxx.

Xxxxxxxx xxxx formoterol, xxxxxxxxxx, xxxxxxxxxx a xxxxxxxxxx, pro xxxxx xx xxx inhalaci xxxxx xxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxx.

X xxxx byla xxxxxxx xxxxxxxx xxxxx terapeutické xxxxxxx, xxxx xxxxx xxxxxxxxxxx (xxxxx plus xxxxxxxxxx) xxxxx xxx 1000 nanogramů x 1 xxxxxxxxx xxxx xxxxxxxxx xx Pozitivní xxxxxxxxxxx xxxxx, xxxxx Xxxxxxxxx xxxxxxxxx, že xxxxxxxxxx xxxxxxxx byl xxxxxxxx xxxxxxxxxxxxx xxxxxxxx xxxxxxxxxxx v xxxxxxxx.

X4. ANTAGONISTÉ X XXXXXXXXXX HORMONŮ

Xxxxxxxxxxx xxxxxxx xxxx xxxxxxxx:

1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:

2. Selektivní modulátory xxxxxxxxxxxxx receptorů (XXXX), xxxxxxxx:

3. Xxxxxxx xxxxxxxxxxxxxx látky xxxxxxxxxx:

4. Xxxxx modifikující xxxxxx xxxxxxxxxx včetně inhibitorů xxxxxxxxxx, ale xx x xxxxxxxx pouze xx xx.

X5. XXXXXXXXX X XXXXXXX XXXXXXXXX XXXXX

Maskovací xxxxx xxxx zakázané. Xxxxxxxx:

Xxxxxxxxx*, epitestosteron, xxxxxxxxxx, xxxxxxxxxx xxxx-xxxxxxxxx (xxxx. xxxxxxxxxx, xxxxxxxxxx), xxxxxxxxxxxxxxx (xxxx. xxxxxxx, xxxxxxx, xxxxxxxxxxxxxxxxx) x xxxxx xxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxxx xxxxxxxx:

Acetazolamid, amilorid, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, kanrenon, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, chlorothiazid), triamteren x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx (xxxxx xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx).

* Xxxxxxxxxxxx xxxxxxx není xxxxxx, xxxxx xxx Xxxxxxxxx xxxxxxxx diuretika ve xxxxxxx x prahovou xxxx xxxxxxxxxxx xxxxxxxx xxxx Xxxxxxxx látky (xxxxx).

X1. XXXXXXXXX XXXXXXX XXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX

M3. XXXXXX XXXXXX

Neterapeutické xxxxxxx xxxxx, xxxx, xxxxxxxx elementů, xxxx xxxxxxxxxx xxxxxxx genů, xxxxx xxxx xxxxxxxxx xxxxxx sportovní xxxxx, xx xxxxxxxx.

X6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx (xxxxxx obou xxxxxx xxxxxxxxxx xxxxxxxxx (X- a L-) xxxxxxx) jsou zakázaná, x výjimkou derivátů xxxxxxxxx v případě xxxxxx místního xxxxx x stimulancií zahrnutých xx Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2008.

Xxxxxxxxxxx xxxxxxxx:

Xxxxxxxxx, xxxxxxxxx**, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxx****, etamivan, xxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, fendimetrazin, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, fenprometamin, xxxxxxxxxxx, xxxxxxxxx, 4-fenylpiracetam (xxxxxxxx), xxxxxxxxxx, xxxxxxxxxx, isomethepten, xxxxx***, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, levmetamfetamin, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx (X-), xxxxxxxxxxxx****, xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, xxxxxxxxxxx, x-xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, strychnin, xxxxxxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxx xxxxxxxx x xxxxx oddíle xxxx xxxxxxxxxx xx xxxxxxxxxxx xxxxx xxxxx, pokud Xxxxxxxxx prokáže, xx xxxx všeobecná dostupnost x xxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxx pravidel, xxxx xx x xxx menší xxxxxxxxxxxxxxx, xx xxxx xxxxxxx xxxxxxxx xxxx dopingová xxxxx.

X7. XXXXXXXXX

Xxxxxxxxxxx xxxxxxxxx xxxx zakázaná:

Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), xxxxxxxx x xxxx deriváty, xxxxxxxxxxx, xxxxxxx, xxxxxx, xxxxxxxx, oxymorfon, pentazocin, xxxxxxx.

S8. XXXXXXXXXXX

Xxxxxxxxxxx (xxxx. xxxxx, xxxxxxxxx) xxxx xxxxxxxx.

S9. XXXXXXXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx xxxx zakázané. Xxxxxx xxxxx xxxxxxxx xxxxxxxxxxxxx výjimku.

Xxxx xxxxxxx injekční xxxxxxxx (xxxxxxxxxxxx, xx okolí xxxxxx, xx xxxxx xxxxxx, xxxxxxxxxx, xx xxxx) x xxxxxxxxx xxxxxxxx vyžadují zkrácenou xxxxxxxxxxxxx xxxxxxx x xxxxxxxx xxxx xxxxxxxxx.

Xxxxxxx xxxxxxxxx xxxxxxxx xx xxxxxx kožní (xxxxxx iontoforézy/fonoforézy), ušní, xxxxx, xxxx, xxxxxx xxxxx xxxxxxx otvoru, xxxxxxxx xxx a xxxxx xxxxxx xxxxxxxx x xxxxxxxxxx xxxxxx xxxxx terapeutické xxxxxxx.

X1. XXXXXXX

Xxxxxxx (xxxxxx) xx xxxxxxxx xxxxx Xxx soutěži x xxxxxxxxxxxxx sportech. Xxxxxxx xx xxxx xxxxxxxx xxxxxxxx xxxxxxxx x/xxxx xxxxxxxx krve. Xxxxxxx xxxxxxx pro porušení xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) xx xxx xxxxxx federaci uvedena x xxxxxxxxx.

∙ Xxxxxxxxxxxx xxxxx (FIA) (0.10 g/l)

∙ Xxxxxx (WKF) (0.10 x/x)

∙ Xxxxxxx xxxxxx a xxxxxxxxxxxx (XXX) (0.20 x/x)

∙ Xxxxxxxxxxx (XXXX, XXX) (0.10 g/l)

∙ Moderní pětiboj (XXXX) xxx pro xxxxxxxxxx xx xxxxxxxx (0.10 x/x)

∙ Xxxxxxxxxxx xxxxx (XXX) (0.10 x/x)

∙ Xxxxx xxxxxxxxxx (XXX) (0.30 x/x)

∙ Xxxxxxx (XXX) (0.10 g/l)

X2. XXXX-XXXXXXXXX

Xxxxx xxxx xxxxx určeno, xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx Při xxxxxxx x následujících sportech.

∙ Automobilový xxxxx (XXX)

∙ Xxxxxxxx (XXXX)

∙ Xxxx (XXXX)

∙ Xxxxx (XXX)

∙ Xxxxxxx (XXX)

∙ Xxxxxxxxxx (XXX)

∙ Jachting (XXXX) - "xxxxx xxxx" - xxx xxxxxxxxxxx

∙ Kuželky (XXX)

∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx (XXX)

∙ Lukostřelba (XXXX, IPC) (xxxxxxxx xxxx Xxxx xxxxxx)

∙ Lyžování (XXX) - xxxxx xx xxxxxx a xxxxxxxxxxx xxxxxxxx-xxxxx a U-rampa, x xxxxxxxxx X-xxxxx x "xxx air"

∙ Xxxxxxx xxxxxxx (XXXX) - xxx xxxxxxxxxx xx xxxxxxxx

∙ Xxxxxxxxxxx xxxxx (XXX)

∙ Xxxxxxxx x xxxxxxx xxxxxx (XXXX, XXX "xxxxx")

∙ Xxxxxxx (XXXX, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)

∙ Xxxxx motorismus (XXX)

∙ Xxxxx (FILA)

Xxxx-xxxxxxxxx xxxxxxxx následující xxxxx:

Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxx, bisoprolol, xxxxxxx, celiprolol, xxxxxxx, xxxxxxxxx, karvedilol, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, metoprolol, xxxxxxx, oxprenolol, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxxx, xxx xx x xxxxxxxx pouze na xx

"Specifické xxxxx"* xxxx vyjmenovány xxxx:

∙ Xxxxxxx Beta-2 xxxxxxxx x xxxxxxxx, xxxxx salbutamolu (xxxxxxx xxxx xxxxxxxxxxx) xxx xxxxxxxx xxxxxx než 1000 xx/xx moči x xxxxxxxxxxxx (zařazen xx xxxxxxx S 1.2 Xxxxxxx anabolické xxxxx);

∙ Inhibitory xxxx-xxxxxxxxx, xxxxxxxxxx;

∙ Xxxxx, kropropamid, krotetamid, xxxxxxx, xxxxxxxx, famprofazon, xxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, meklofenoxát, x-xxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, norfenefrin, xxxxxxxxx, xxxxxxxxx, oxilofrin, xxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxx a xxxxxxx xxxxxxx xxxxxxxxxxx neuvedená xxxxxxxx v xxxxxx X6, xxx která Xxxxxxxxx xxxxxxx, že xxxxxxx xxxxxxxx xxxxxxx x xxxxxx X6;

∙ Kanabinoidy;

∙ Xxxxxxx Xxxxxxxxxxxxxxxxxxxx;

∙ Xxxxxxx;

∙ Všechny Xxxx-xxxxxxxxx.

*"X Xxxxxxx xxxxx xxx xxxxxxxxxxx xxxxxxxxxx xxxxx, xxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxx pravidel, xxxxxxx xxxx xxxxxxxxx xxxxxxxx x xxxxxxx xxxxxxxxx xxxxxxxxxxx, xxxx x xxxxx je xxxxx xxxxxxxxxxxxxxx, xx xxxxx úspěšně zneužity xxxx xxxxxxxxx xxxxxxx." Xxxxxxxx xxxxxxxxxxxxxxx pravidla xxxxxxxxxx takovéto xxxxx xxxx xxxxxxxx xxxxxxx xxxxxx za xxxxxxxxxxx, xx "...Xxxxxxxxx xxxx xxxxx prokázat, že Xxxxxxx xxxxxxxxxx xxxxx xxxxxx xxxxxxxxx ke xxxxxxx sportovního xxxxxx...".

Xxxxxx xxxxxxx x. 2/2008 Xx. x. x. nabyl xxxxxxxxx xxxx 31.1.2008.

Xxxxxx xxxxxxx č. 2/2008 Xx. x. x. xxx xxxxxx xxxxxxx xxxxxxxxx č. 8/2009 Sb. m. s. x xxxxxxxxx xx 7.2.2009.

Xxxxx xxxxxxxxxxxx právních xxxxx xxxxxx právních xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, pokud se xxxx netýká xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.